drugset / Trial / NCT00652561
Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer
Phase 2
Completed
57 enrolled
Taiho Oncology, Inc.
Quintiles, Inc. · collabUnited BioSource, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether S-1 is effective as 2nd line therapy in slowing tumor activity in patients with advanced non-small cell lung cancer. The study is also looking at the safety of S-1.
Timeline
- Start
- 2005-02
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | S-1 | Small molecule | 30 mg/m2 | Oral |